Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women
NCT ID: NCT03212781
Last Updated: 2017-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
66 participants
INTERVENTIONAL
2016-06-30
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Antenatal Support for Iron Deficiency Anemia
NCT04278651
Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial
NCT03830034
Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy
NCT02086838
Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women
NCT03378791
Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement
NCT02957643
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intravenous iron
patients will receive intravenous iron as total dose infusion
Iron dextran
total dose infusion
oral iron
patients will receive oral iron
Ferrous Fumarate
oral tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iron dextran
total dose infusion
Ferrous Fumarate
oral tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age between 14-28 weeks.
* Willingness to participate and signing the informed consent form.
Exclusion Criteria
* Decompensated liver cirrhosis and active hepatitis
* Active acute or chronic infections
* History of multiple allergies
* Known hypersensitivity to parenteral iron or any recipients in the investigation drug products
* Erythropoietin treatment within 8 weeks prior to the screening visit
* Other iron treatment or blood transfusion within 4 weeks prior to the screening visit
* Planned elective surgery during the study.
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mohamed Abbas
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut Faculty of Medicine
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDAO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.